• Regulatory NewsRegulatory News

    UK Industry Group Sees More Complaints Against Pharma Members in 2016

    The Prescription Medicines Code of Practice Authority (PMCPA), which oversees the Association of the British Pharmaceutical Industry's (ABPI) code of practice, says it saw more complaints about drugmakers' promotional materials and activities in 2016 than in the previous year. In 2016, PMCPA saw a 41% jump in the number of complaints it received over 2015, with 76 complaints compared to 54. These complaints led to 100 cases covering 420 individual matters, as many of the...
  • Regulatory NewsRegulatory News

    Celgene, Takeda and Others Found in Breach of UK’s Pharma Code of Practice

    When is it OK for a pharmaceutical company to fail to quality check bags stored in a basement for three years before supplying them to pharmacies to use when dispensing the chemotherapy Navelbine (vinorelbine) to patients? Apparently never, according to Tuesday’s rundown of companies breaching the Association of British Pharmaceutical Industry’s (APBI) Code of Practice. In addition to the basement storage fiasco for the French company Pierre Fabre, which the UK’s Pr...
  • Regulatory NewsRegulatory News

    MHRA Raises Concerns Over Improper Biosimilar Marketing

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday unveiled its misgivings with a two-day promotional meeting for UK health professionals on the Remicade (infliximab) biosimilar Remsima in Norway. The meeting, entitled “Norway inflammatory bowel disease [IBD] exchange,” was intended by the privately held, UK-based Napp Pharmaceuticals to promote Remsima from 11-13 October 2015 for UK healthcare professionals. The meeting was ruled in breach of...